Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gynecologic Oncology
•
Cervical Cancer
How would you approach unresectable pelvic side wall recurrence in cervical cancer with previous definitive chemoradiation?
Would you consider SBRT or brachytherapy?
Answer from: Radiation Oncologist at Community Practice
I would start with palliative chemo and if good response, plan for SBRT for residual disease with the dose based on OAR.
Comments
Radiation Oncologist at UAB Department of Radiation Oncology
I agree with the above comments. This is one of th...
Radiation Oncologist at Baylor College of Medicine
What dose constraints have you been following for ...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
Ling et al., PMID 31150869
Radiation Oncologist at Emeritus Professor
The definition of unresectable pelvic sidewall rec...
3340
3344
3346
3372
Sign in or Register to read more
8198
Related Questions
What are some considerations for planning T&O brachytherapy in a patient with bilateral hip replacements, where it is difficult to delineate disease on MRI and even surrounding structures on CT?
Are there patient populations in whom you would consider using both induction chemotherapy and maintenance pembrolizumab for a patient with locally advanced cervical cancer?
How would you utilize brachytherapy boost in addition to EBRT for HPV-dependent invasive squamous cell carcinoma present as a large pelvic side wall mass, presumed to be of cervix primary, albeit the negative biopsies of the cervix?
Would you offer post operative radiation for a patient who had findings of lymphovascular invasion on salvage resection of a recurrent obturator node after definitive chemoradiation for cervical cancer?
In patients getting concurrent chemo-immunotherapy for locally advanced cervix cancer, would you hold immunotherapy during the 2.5-3 weeks of brachytherapy?
Do you have concerns about the validity of the INTERLACE data, considering the long study recruitment period (10 years) and evolution of radiation techniques that have occurred during that time frame?
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?
With the addition of pembrolizumab following chemoradiation per KEYNOTE-A18, would you be less likely to treat the paraaortic chain prophylactically?
How do you counsel patients about prognosis with FIGO 2018 IIIC cervix cancer managed in the new era of chemoradiation plus immunotherapy?
Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?
I agree with the above comments. This is one of th...
What dose constraints have you been following for ...
Ling et al., PMID 31150869
The definition of unresectable pelvic sidewall rec...